Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Werewolf TherapeuticsHOWL -4.02%32 EV-to-EBIT is 0.11 as of Aug. 10, 2026, which is 175% above its 10-year median of 0.04. GuruFocus rates HOWL with a GF Score™ of 32/100 and a GF Value™ of $3.78 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 370 Biotechnology companies, Werewolf Therapeutics ranks better than 94.86% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Werewolf Therapeutics's Enterprise Value for the quarter that ended in Jun. 2026 was $-4.50 Mil.
Werewolf Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-30.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Werewolf Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Werewolf Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Werewolf Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Werewolf Therapeutics's EV-to-EBIT falls into.
Werewolf Therapeutics's current Enterprise Value is $-3.42 Mil.
Werewolf Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-30.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Werewolf Therapeutics (HOWL) has a EV-to-EBIT of 0.11 as of Aug. 10, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Werewolf Therapeutics and its competitors. This is 175% above median its historical median of 0.04. According to the industry distribution chart, Werewolf Therapeutics ranks #19 out of 370 companies in the Biotechnology industry, placing it in the top 5.1%.
Is Werewolf Therapeutics' EV-to-EBIT too high?
Werewolf Therapeutics' current EV-to-EBIT of 0.11 is 175% above median its 10-year median of 0.04. The Biotechnology industry median EV-to-EBIT is 15.03. Werewolf Therapeutics' value of 0.11 is 99.3% below this industry median. Based on the distribution chart, Werewolf Therapeutics ranks #19 out of 370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Werewolf Therapeutics has a GF Score™ of 32/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Werewolf Therapeutics' EV-to-EBIT compare to CVM and MRKR?
According to the Biotechnology industry distribution chart, Werewolf Therapeutics ranks #19 out of 370 companies for EV-to-EBIT. This places Werewolf Therapeutics in the top 5% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.03. Werewolf Therapeutics' value of 0.11 is 99.3% below this benchmark. While the company's 10-year median is 0.04 vs. the industry median of 15.03, Werewolf Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.03, based on 370 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Werewolf Therapeutics's current EV-to-EBIT of 0.11 is 99.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Werewolf Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Werewolf Therapeutics's current EV-to-EBIT is 0.11, which is 175% above median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Werewolf Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Werewolf Therapeutics (HOWL) is currently considered Possible Value Trap. The stock's GF Value™ is $3.78, compared to a current price of $0.38 — trading 89.9% below its estimated fair value. The current EV-to-EBIT is 0.11, which is 175% above median its 10-year median of 0.04 and 99.3% below the Biotechnology industry median of 15.03. Werewolf Therapeutics' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Werewolf Therapeutics (HOWL), the current EV-to-EBIT is 0.11 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Werewolf Therapeutics (HOWL) Overvalued in 2026?
Based on GuruFocus' analysis, Werewolf Therapeutics stock appears to be undervalued.
The current stock price of $0.38 is trading 89.9% below its estimated GF Value™ of $3.78.
GuruFocus considers Werewolf Therapeutics to be Possible Value Trap.
Key valuation signals for HOWL:
EV-to-EBIT: 0.11 (175% above median its 10-year median of 0.04)
GF Value™: $3.78 vs. price of $0.38 (89.9% below fair value)
Industry Position: 99.3% below the Biotechnology median (#19 of 370)
No single metric tells the full story. See the HOWL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.
32GF Score
Get the complete analysis for HOWL
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HOWL has been successfully added to your 
